The stock value of Novavax, Inc (NASDAQ: NVAX) had a significant increase of 22.61% in the last session, ending at $4.88. The completion of a settlement agreement led to this rise in Novavax’s stock price.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The cooperation between Gavi, the Vaccine Alliance, and Novavax (NVAX) has paid off as the parties have reported that issues with the 2021 Advance Purchase Agreement (APA) involving Novavax’s COVID-19 prototype vaccine (NVX-CoV2373) have been resolved. This agreement essentially ends the ongoing arbitration related to the APA.
Novavax expresses satisfaction in achieving this accord with Gavi, recognizing its significance in enabling continued collaboration towards the common objective of ensuring universal access to safe and efficacious vaccines. With Gavi, NVAX is now ready to build a long-term collaboration that will guarantee the continuous supply of protein-based non-mRNA COVID-19 vaccines.
With this arrangement, Gavi is able to continue concentrating on core programming goals, such helping underprivileged populations in economically challenged areas obtain COVID-19 vaccinations. It stands as a testament to global immunization efforts, bolstering national health initiatives and fostering robust manufacturing markets.
Aligned with a shared dedication to public health, Novavax and Gavi have delineated terms that prioritize their mutual commitment to preserving lives and safeguarding health by enhancing equitable and sustainable vaccine utilization. Pursuant to these terms, Novavax has disbursed an initial sum of $75 million to Gavi.
Furthermore, NVAX has committed to subsequent payments of $80 million annually until December 31, 2028, disbursed in quarterly increments, amounting to a total of $400 million. Novavax’s annual financial obligation will be offset or diminished by an $80 million yearly vaccine credit, applicable to qualifying sales of any of the Company’s vaccines funded by Gavi, earmarked for distribution in low-income and lower-middle income countries.
Utilization of the annual vaccine credit for eligible sales will alleviate Novavax’s annual monetary commitment. In addition to this commitment, Novavax pledges an additional vaccine credit of up to $225 million, contingent upon demand, to be utilized for qualifying dosage purchases of the Company’s vaccines within such countries over the duration of the five-year term.
